Aurora Therapeutics halts lead CRISPR program and cuts staff
read at Endpoints ↗LayoffsNegative
Aurora Therapeutics, founded as the first company dedicated to developing custom CRISPR-based gene-editing medicines, announced a major restructuring.
The firm said it is laying off several employees and has halted development of its lead program, which was based on CRISPR base editing to correct disease-causing mutations.
The move puts the startup's future in doubt and highlights the challenges of translating bespoke gene-editing approaches into viable commercial products.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “An uncertain future for Aurora, the first startup dedicated to custom CRISPR therapies”
read at Endpoints ↗86 words · retrieved 9h ago
comments(0)
5-min edit window · permanent after that